Pharmacogenomics Principles: Introduction to Personalized Medicine

Pharmacogenomics in Clinical Therapeutics

Volumn , Issue , 2012, Pages 1-14

  Madadi, Parvaz ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Drug response; Genome sequencing; Personalized medicine; pharmacogenomics; Single gene polymorphism

Indexed keywords

EID: 84887153020     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959601.ch1     Document Type: Chapter

References (76)

1. World Health Organization Adherence to Long Term Therapies Project and the Global Adherence Interdisciplinary Network (2003) Adherence to Long-Term Therapies: Evidence for Action. World Health Organization, Geneva.
2. Osterberg, L., Blaschke, T. (2005) Adherence to medication. New England Journal of Medicine, 353(5), 487-497.
3. Stephenson, J. (1999) Noncompliance may cause half of antihypertensive drug "failures." Journal of the American Medical Association, 282(4), 313-314.
4. Sultana, G., Kapur, P., Aqil, M., Alam, M.S., Pillai, K.K. (2010) Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. Journal of Clinical and Pharmaceutical Therapies, 35(3), 267-277.
5. Wong, M.C., Jiang, J.Y., Griffiths, S.M. (2010) Factors associated with antihypertensive drug compliance in 83,884 Chinese patients: a cohort study. Journal of Epidemiology and Community Health, 64(10), 895-901.
6. Haynes, R.B., McDonald, H., Garg, A.X., Montague, P. (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Systems Review (2) CD000011.
7. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S., Kauffman, R.E. (2003) Developmental pharmacology: drug disposition, action, and therapy in infants and children. New England Journal of Medicine, 349(12), 1157-1167.
8. Koren, G. (1997) Therapeutic drug monitoring principles in the neonate. Clinical Chemistry, 43(1), 222-227.
9. Assael, B.M. (1982). Pharmacokinetics and drug distribution during postnatal development. Pharmacological Therapies, 18(2), 159-197.
10. Choonara, I.A., McKay, P., Hain, R., Rane, A. (1989) Morphine metabolism in children. British Journal of Clinical Pharmacology, 28(5), 599-604.
11. Lynn, A.M., Slattery, J.T. (1987). Morphine pharmacokinetics in early infancy. Anesthesiology, 66(2), 136-139.
12. Pacifici, G.M., Sawe, J., Kager, L., Rane, A. (1982) Morphine glucuronidation in human fetal and adult liver. European Journal of Clinical Pharmacology, 22(6), 553-558.
13. Coffman, B.L., King, C.D., Rios, G.R., Tephly, T.R. (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metabolism and Disposal, 26(1), 73-77.
14. Coffman, B.L., Rios, G.R., King, C.D., Tephly, T.R. (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metabolism and Disposal, 25(1), 1-4.
15. Anderson, B.J., McKee, A.D., Holford, N.H. (1997) Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clinical Pharmacokinetics, 33(5),313-327.
16. de Wildt, S.N., Kearns, G.L., Leeder, J.S., van den Anker, J.N. (1999) Glucuronidation in humans: pharmacogenetic and developmental aspects. Clinical Pharmacokinetics, 36(6), 439-452.
17. McCarver, D.G., Hines, R.N. (2002) The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. Journal of Pharmacological and Experimental Therapies, 300(2), 361-366.
18. Klassen, T.P., Hartling, L., Craig, J.C., Offringa, M. (2008) Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Medicine, 5(8), e172.
19. Barnett, S.R. (2009) Polypharmacy and perioperative medications in the elderly. Anesthesiology Clinics, 27(3), 377-389.
20. Pollock, B., Forsyth, C., Bies, R. (2009) The critical role of clinical pharmacology in geriatric psychopharmacology. Clinical and Pharmaceutical Therapies, 85(1), 89-93.
21. Meyers, B.S., Jeste, D.V. (2010) Geriatric psychopharmacology: evolution of a discipline. Journal of Clinical Psychiatry, 71(11), 1416-1424.
22. Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L., Abul-Ezz, S.R. (2000) Drug interaction between St. John's wort and cyclosporine. Annals of Pharmacotherapy, 34(9), 1013-1016.
23. Wilkinson, G.R. (2005) Drug metabolism and variability among patients in drug response. New England Journal of Medicine, 352(21), 2211-2221.
24. Flockhart, D.A. (2007) Drug interactions: cytochrome P450 drug interaction table [WWW document]. URL http://medicine.iupui.edu/clinpharm/ddis/table.asp [accessed on 17 June 2011]
25. Salphati, L., Benet, L.Z. (1998) Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochemistry and Pharmacology, 55(4), 387-395.
26. Bailey, D.G., Malcolm, J., Arnold, O., Spence, J.D. (2004) Grapefruit juice-drug interactions. 1998. British Journal of Clinical Pharmacology, 58(7), S831-S840; discussion, S841-S843.
27. Mooradian, A.D. (1988) Digitalis: an update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clinical Pharmacokinetics, 15(3), 165-179.
28. Amabile, C.M., Bowman, B.J. (2006) Overview of oral modified-release opioid products for the management of chronic pain. Annals of Pharmacotherapy, 40(7-8), 1327-1335.
29. Haas, D.M., Hebert, M.F., Soldin, O.P., Flockhart, D.A., Madadi, P., Nocon, J.J., et al. (2009) Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy. Clinical and Translational Science, 2(6), 439-443.
30. Andrew, M.A., Easterling, T.R., Carr, D.B., Shen, D., Buchanan, M.L., Rutherford, T., et al. (2007) Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clinical and Pharmaceutical Therapies, 81(4), 547-556.
31. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. (2007). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811):525-8.
32. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. (2006). Global variation in copy number in the human genome. Nature 444(7118):444-54.
33. Eichler EE. (2008). Copy number variation and human disease. Nature Education 1(3): http://www.nature.com/scitable/topicpage/copy-number-variation-andhuman- disease-741737.
34. Meyer UA. (2004). Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5(9):669-76.
35. Evans DA. (1968). Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci 151(2):723-33.
36. Evans DA, White TA. (1964). Human Acetylation Polymorphism. J Lab Clin Med 63:394-403.
37. Kalow W. (1971). Topics in pharmacogenetics. Ann N Y Acad Sci; 179:654-9.
38. Krishnamurthy DV, Selkon JB, Ramachandran K, Devadatta S, Mitchison DA, Radhakrishna S, et al. (1967). Effect of pyridoxine on vitamin B6 concentrations and glutamic-oxaloacetic transaminase activity in whole blood of tuberculous patients receiving high-dosage isoniazid. Bull World Health Organ 36(5):853-70.
39. Clayman CB, Arnold J, Hockwald RS, Yount EH, Jr., Edgcomb JH, Alving AS. (1952). Toxicity of primaquine in Caucasians. J Am Med Assoc 149(17):1563-8.
40. Beutler E. (1994). G6PD deficiency. Blood 84(11): 3613-36.
41. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, et al. (2010). Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 33(9):713-26.
42. Kalow W. (1952). Hydrolysis of local anesthetics by human serum cholinesterase. J Pharmacol Exp Ther 104(2):122-34.
43. Kalow W, Genest K. (1957). Amethod for the detection of atypical forms ofhumanserum cholinesterase; determination of dibucaine numbers. Can J Biochem Physiol 35(6):339-46.
44. Kalow W, Genest K, Staron N. (1956). Kinetic studies on the hydrolysis of benzoylcholine by human serum cholinesterase. Can J Biochem Physiol 34(3):637-53.
45. Kalow W, Lindsay HA. (1955). A comparison of optical and manometric methods for the assay ofhumanserum cholinesterase. Can J Biochem Physiol 33(4):568-74.
46. Kalow W, Maykut MO. (1956). The interaction between cholinesterases and a series of local anesthetics. J Pharmacol Exp Ther 116(4):418-32.
47. Kalow W, Staron N. (1957). On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 35(12):1305-20.
48. Kalow W. (1995). Life of a pharmacologist or the rich life of a poor metabolizer. Pharmacol Toxicol 76(4):221-7.
49. Rubinstein HM, Dietz AA, Lubrano T. (1978). E1k, another quantitative variant at cholinesterase locus 1. J Med Genet 15(1):27-9.
50. Daly AK. (2010). Pharmacogenetics and human genetic polymorphisms. Biochem J 429(3):435-49.
51. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. (1979). Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16(3):183-7.
52. Smith RL.The Paton Prize Award. (2001). The discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. Toxicology 168(1):11-9.
53. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewka J, et al. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 1987; 6(2):149-61.
54. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. (1988). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331(6155):442-6.
55. Yu AM, Idle JR, Gonzalez FJ. (2004). Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36(2):243-77.
56. Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ. (2003). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine Odemethylase. Pharmacogenetics 13(6):307-19.
57. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. (2008). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical and Pharmaceutical Therapies, 83(2), 234-242.
58. Weinshilboum RM,Sladek SL. (1980). Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651-62.
59. Lennard L, Van Loon JA, Weinshilboum RM. (1989). Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical and Pharmaceutical Therapies, 46(2), 149-154.
60. Evans, W.E., Horner, M., Chu, Y.Q., Kalwinsky, D., Roberts, W.M. (1991) Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. Journal of Pediatrics, 119(6), 985-989.
61. Weinshilboum, R.M., Sladek, S., Klumpp, S. (1979) Human erythrocyte thiol methyltransferase: radiochemical microassay and biochemical properties. Clinica Chimica Acta: International Journal of Clinical Chemistry, 97(1), 59-71.
62. Lennard, L. (1987) Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. Journal of Chromatography, 423,169-178.
63. Appell, M.L.,Wennerstrand, P., Peterson, C., Hertervig, E., Martensson, L.G. (2010) Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene. Pharmacogenetic Genomics, 20(11), 700-707.
64. Wang, L., Weinshilboum, R. (2006) Thiopurine Smethyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene, 25(11), 1629-1638.
65. Roberts, R.L., Gearry, R.B., Bland, M.V., Sies, C.W., George, P.M., Burt,M., et al. (2008) Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferasegeneofpatientsexhibitingultra-highenzyme activity. Pharmacogenetic Genomics, 18(5), 434-438.
66. Freedman, A.N., Sansbury, L.B., Figg,W.D., Potosky, A. L., Weiss Smith, S.R., Khoury, M.J., et al. (2010) Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. Journal of the National Cancer Institute, 102(22), 1698-1705.
67. Kalow, W. (2006) Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics Journal, 6(3), 162-165.
68. Rotimi, C.N., Jorde, L.B. (2010) Ancestry and disease in the age of genomic medicine. New England Journal of Medicine, 363(16), 1551-1558.
69. Ashley, E.A., Butte, A.J., Wheeler, M.T., Chen, R., Klein, T.E., Dewey, F.E., et al. (2010) Clinical assessment incorporating a personal genome. Lancet, 375(9725), 1525-1535.
70. Butte, A.J. (2008). Medicine: the ultimate model organism. Science, 320(5874), 325-327.
71. Ormond, K.E., Wheeler, M.T., Hudgins, L., Klein, T.E., Butte, A.J., Altman, R.B., et al. (2010) Challenges in the clinical application of whole-genome sequencing. Lancet, 375(9727), 1749-1751.
72. Butte, A.J. (2009). Translational bioinformatics applications in genome medicine. Genome Medicine, 1(6), 64.
73. American Medical Informatics Association (2011) AMIA strategic plan [WWW document]. URL https://www.amia.org/inside/initiatives [accessed on 17 June 2011].
74. Collins, F.S., Guttmacher, A.E. (2001) Genetics moves into the medical mainstream. Journal of the American Medical Association, 286(18), 2322-2324.
75. National Human Genome Research Institute (2011) [Home page] [WWW document]. URL http://www.genome.gov/27527634 [accessed on 17 June 2011]
76. Smerecnik, C.M., Mesters, I., de Vries, N.K., de Vries, H. (2008) Educating the general public about multifactorial genetic disease: applying a theory-based framework to understand current public knowledge. Genetics in Medicine, 10(4), 251-258.